The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid.

Vogensen, Vanessa BAnthony, Richard MKerstjens, Huib A MTiberi, Simonde Steenwinkel, Jurriaan E MAkkerman, Onno W2022-04-122022-04-122022-04-013537827110.1016/j.cmi.2022.03.033http://hdl.handle.net/10029/625701enThe case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid.Article1469-0691Clinical microbiology and infection 2022; 28(8):1047-1049